In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33+ Acute Myeloid Leukemia

@inproceedings{Dutour2012,
  title={
					In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33+ Acute Myeloid Leukemia},
  author={Aur{\'e}lie Dutour and V. Terribile Wiel Marin and Irene Pizzitola and Sandrine Valsesia-Wittmann and Amanda J Lee and Eric S Yvon and Helene M. Finney and Alastair D G Lawson and Malcolm K. Brenner and Andrea Biondi and Ettore Biagi and Rapha{\"e}l Rousseau},
  booktitle={Advances in hematology},
  year={2012}
}
Genetic engineering of T cells with chimeric T-cell receptors (CARs) is an attractive strategy to treat malignancies. It extends the range of antigens for adoptive T-cell immunotherapy, and major mechanisms of tumor escape are bypassed. With this strategy we redirected immune responses towards the CD33 antigen to target acute myeloid leukemia. To improve in vivo T-cell persistence, we modified human Epstein Barr Virus-(EBV-) specific cytotoxic T cells with an anti-CD33.CAR. Genetically modified… CONTINUE READING